Pegylated IFN-alpha 2b

Phase 3Small molecule

GGynecologic Oncology Group

Pegylated IFN-alpha 2b is one of 107 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

106

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerCompleted

Pancreatic CancerActive, not recruiting

Locally Advanced Malignant Solid NeoplasmRecruiting

Anatomic Stage IV Breast Cancer AJCC V8Recruiting

Ductal Carcinoma in SituUnknown status

Metastatic Dedifferentiated LiposarcomaRecruiting

Fallopian Tube High Grade Serous AdenocarcinomaActive, not recruiting

Endometrioid AdenocarcinomaActive, not recruiting

FIGO Stage IVA Ovarian CancerActive, not recruiting

Breast CancerPhase 3

Completed

Pancreatic CancerPhase 2

Active, not recruiting

Locally Advanced Malignant Solid NeoplasmPhase 2

Recruiting

Anatomic Stage IV Breast Cancer AJCC V8Phase 2

Recruiting

Ductal Carcinoma in SituPreclinical

Unknown status

Metastatic Dedifferentiated LiposarcomaPhase 1

Recruiting

Fallopian Tube High Grade Serous AdenocarcinomaPreclinical

Active, not recruiting

Endometrioid AdenocarcinomaPhase 1

Active, not recruiting

FIGO Stage IVA Ovarian CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Pegylated IFN-alpha 2b

GGynecologic Oncology Group

Phase 3

13 2

Voltaren

Novartis

Preclinical

1 3

Zolymbus

AbbVie

Preclinical

1 4

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 6

Duragesic-100

CCephalon

Preclinical

2 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 8

Spravato

WWim Janssens

Preclinical

2 9

Duragesic

CCephalon

Preclinical

1 10

Tricor

JJagotec

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

FIGO Stage IVA Ovarian Cancer

NCT01970722

PreclinicalActive, not recruiting

Fallopian Tube Clear Cell Adenocarcinoma

NCT02502266

Phase 3Active, not recruiting

Fallopian Tube Clear Cell Adenocarcinoma

NCT02446600

Q2 2027

Phase 1Recruiting

Metastatic Dedifferentiated Liposarcoma

NCT05711615

PreclinicalActive, not recruiting

Fallopian Tube High Grade Serous Adenocarcinoma

NCT02839707

Phase 2Recruiting

Locally Advanced Malignant Solid Neoplasm

NCT03907475

Clinical

Trials by Indication[1]

Breast Cancer13 trials

Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer

Completed·UUniversity of Washington·Phase 1/2·NCT00331552·30 enrolled

Comparison of Two Regimens of Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00005980·116 enrolled

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer

Active, not recruiting·RRutgers, The State University of New Jersey·Phase 2·NCT02315196·62 enrolled

Show 10 more trials

Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer

Unknown status·PPharmatech Oncology·Phase 2·NCT00027989

Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery

Terminated·RRoswell Park Cancer Institute·Phase 2·NCT00524459·6 enrolled

Doxorubicin Hydrochloride Liposome as First-Line Therapy in Treating Older Women With Metastatic Breast Cancer

Completed·AARCAGY/ GINECO GROUP·Phase 2·NCT00960336·59 enrolled

Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer

Recruiting·RRoswell Park Cancer Institute·Phase 2·NCT06434064·30 enrolled

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00004888·84 enrolled

Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00004925

Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer

Completed·NNYU Langone Health·Phase 1/2·NCT00006825

Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer

Terminated·EETOP IBCSG Partners Foundation·Phase 3·NCT00296010·77 enrolled

Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00005991·76 enrolled

F511 Cream in Preventing Palmar-Plantar Erythrodysesthesia in Patients Receiving Doxorubicin Hydrochloride Liposome for Metastatic Breast Cancer

Completed·SSwiss Cancer Institute·Phase 3·NCT00992706·91 enrolled

Multiple Myeloma8 trials

Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Unknown status·OOncotherapeutics·Phase 2·NCT00742404·35 enrolled

Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00088855·55 enrolled

Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma

Terminated·UUniversity of Washington·Phase 1/2·NCT00849251·31 enrolled

Show 5 more trials

Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00523848·46 enrolled

Combination Chemotherapy in Treating Patients With Multiple Myeloma

Completed·TThe Cleveland Clinic·Phase 2·NCT00003493

Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma

Unknown status·HHerbert Irving Comprehensive Cancer Center·Phase 1/2·NCT00334932·32 enrolled

Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00458705·45 enrolled

Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma

Terminated·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT00744354·32 enrolled

Liposomal Doxorubicin8 trials

Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers

Completed·WWashington University School of Medicine·Phase 1·NCT00003207·14 enrolled

Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02456857·17 enrolled

Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer

Unknown status·UUniversity of Leicester·Phase 2·NCT00004236

Show 5 more trials

Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00020449

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Completed·GGynecologic Oncology Group·Phase 1·NCT01294293·20 enrolled

Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

Terminated·GGynecologic Oncology Group·Phase 1·NCT00003380

Liposomal Doxorubicin in Treating Patients With Persistent or Recurrent Cancer of the Cervix

Terminated·GGynecologic Oncology Group·Phase 2·NCT00030472

Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer

Completed·AAGO Study Group·Phase 1/2·NCT00032162·63 enrolled

Lymphoma8 trials

Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00003388·38 enrolled

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 1/2·NCT00006029·91 enrolled

SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00337194·30 enrolled

Show 5 more trials

ZD0473 and Doxorubicin in Treating Patients With Advanced Solid Tumors or Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00016172

Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed·RRoswell Park Cancer Institute·Phase 1/2·NCT00244985·42 enrolled

Liposomal Doxorubicin Plus Combination Chemotherapy in Treating Patients With AIDS-Associated Non-Hodgkin's Lymphoma

Completed·UUniversity of Alabama at Birmingham·Phase 1·NCT00004162·48 enrolled

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma

Completed·AAIDS Malignancy Consortium·Phase 2·NCT00389818·43 enrolled

A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

Withdrawn·NNational Cancer Institute (NCI)·Phase 3·NCT05711628

Fallopian Tube Cancer7 trials

Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01459380·41 enrolled

Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Completed·RRoswell Park Cancer Institute·Phase 1·NCT01673217·18 enrolled

EGEN-001 and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Completed·GGynecologic Oncology Group·Phase 1·NCT01489371·16 enrolled

Show 4 more trials

Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract

Completed·NNYU Langone Health·Phase 2·NCT00003334

Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer

Completed·GGynecologic Oncology Group·Phase 1·NCT00003385·48 enrolled

Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01145430·45 enrolled

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Completed·MMayo Clinic·Phase 2·NCT02312245·13 enrolled

33 more indications

Ovarian Cancer5 trials

p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

Completed·AAprea Therapeutics·Phase 2·NCT03268382·36 enrolled

S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer

Completed·SSWOG Cancer Research Network·Phase 3·NCT00043082·61 enrolled

Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT05295589

Show 2 more trials

A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072)(COMPLETED)

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00727961·58 enrolled

Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00182767·45 enrolled

Kaposi's sarcoma2 trials

Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma

Completed·RRoswell Park Cancer Institute·Phase 3·NCT00002985

Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00003350·240 enrolled

Soft Tissue Sarcoma2 trials

Liposomal Doxorubicin Plus Ifosfamide in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 1·NCT00030784·28 enrolled

PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma

Completed·MMasonic Cancer Center, University of Minnesota·N/A·NCT00346125·70 enrolled

Prostate Cancer2 trials

Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer

Completed·IImunon·Phase 1·NCT00061867

Liposomal Doxorubicin in Treating Patients With Prostate Cancer

Completed·—·Phase 2·NCT00004014·10 enrolled

Endometrial Cancer2 trials

Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer

Terminated·RRoswell Park Cancer Institute·Phase 2·NCT00470067·9 enrolled

Liposomal Doxorubicin in Treating Patients With Advanced or Recurrent Endometrial Cancer

Completed·GGynecologic Oncology Group·Phase 2·NCT00005861

Diffuse Large B-Cell Lymphoma2 trials

Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00101010·80 enrolled

Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

Terminated·RRoswell Park Cancer Institute·Phase 2·NCT00851552·9 enrolled

Fallopian Tube Clear Cell Adenocarcinoma2 trials

A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)

Active, not recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT02502266·582 enrolled

A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT02446600·579 enrolled

Bile Duct Cancer1 trial

Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer

Unknown status·—·Phase 2·NCT00003296·26 enrolled

Gynecologic Cancer1 trial

A Study of Carboplatin, PLD and Everolimus in Certain Gynecologic Cancer

Completed·FFox Chase Cancer Center·Phase 1·NCT01281514·21 enrolled

Ductal Carcinoma in Situ1 trial

Doxorubicin Hydrochloride Liposome in Treating Women With Ductal Carcinoma in Situ Undergoing Surgery

Unknown status·—·N/A·NCT00671476·30 enrolled

Pancreatic Cancer1 trial

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Active, not recruiting·OOHSU Knight Cancer Institute·Phase 2·NCT06630325·30 enrolled

Chronic Hepatitis1 trial

Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis Genotype 4

Completed·—·Phase 4·NCT00277862·280 enrolled

Primary Peritoneal Cancer1 trial

Liposomal Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed·GGynecologic Oncology Group·Phase 1·NCT00006235

Renal Cell Carcinoma1 trial

Study of Ixazomib With Pegylated IFN-alpha 2b (pIFN) in Metastatic Renal Cell Carcinoma (mRCC)

Terminated·FFox Chase Cancer Center·Phase 1/2·NCT02447887·3 enrolled

Cervical Cancer1 trial

Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer

Unknown status·TThe University of Texas Health Science Center, Houston·Phase 2·NCT00003135·34 enrolled

Patients With Advanced Solid Tumors1 trial

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Completed·—·Phase 1·NCT00006372·10 enrolled

Chemotherapy1 trial

Chemotherapy in Treating Patients With Sarcoma of the Uterus

Completed·GGynecologic Oncology Group·Phase 2·NCT00005643

Patients With Solid Tumors1 trial

VX-853 in Treating Patients With Solid Tumors Who Are Receiving Liposomal Doxorubicin

Completed·GGeorgetown University·Phase 1/2·NCT00004030·45 enrolled

Hematologic Cancer1 trial

Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00003243

Stage IV Ovarian Epithelial Cancer1 trial

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Completed·GGynecologic Oncology Group·Phase 3·NCT00011986·4,312 enrolled

Cutaneous T-cell lymphoma1 trial

Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00255801·37 enrolled

Mycosis Fungoides1 trial

Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00074087·49 enrolled

Peritoneal Cancer1 trial

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Terminated·MMayo Clinic·Phase 2·NCT02364713·17 enrolled

Metastatic Dedifferentiated Liposarcoma1 trial

A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin in Patients With Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas

Recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT05711615·30 enrolled

Fallopian Tube High Grade Serous Adenocarcinoma1 trial

A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT02839707·444 enrolled

FIGO Stage IVA Ovarian Cancer1 trial

Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Optional Postoperative Normothermic Intraperitoneal (IP) Chemotherapy to Treat Primary or Recurrent Carcinoma of Ovarian, Fallopian Tube, Uterine, or Peritoneal Origin

Active, not recruiting·CCity of Hope Medical Center·Phase 1·NCT01970722·40 enrolled

Plasma Cell Leukemia1 trial

Phase 1 Study of Daratumumab When Given in Combination With Bortezomib, Dexamethasone, Doxil, and Lenalidomide in Patients With Plasma Cell Leukemia

Withdrawn·CCity of Hope Medical Center·Phase 1·NCT03591744

Fallopian Tube Mucinous Adenocarcinoma1 trial

A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT04739800·120 enrolled

Locally Advanced Malignant Solid Neoplasm1 trial

DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors

Recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03907475·115 enrolled

Anatomic Stage IV Breast Cancer AJCC v81 trial

A Phase II Trial of the Immunogenicity of a DNA Plasmid-Based Vaccine (STEMVAC) Encoding Th1 Selective Epitopes From Five Antigens Associated With Breast Cancer Stem Cells (MDM2, YB1, SOX2, CDH3, CD105) in Patients With Metastatic Triple-Negative Breast Cancer

Recruiting·UUniversity of Washington·Phase 2·NCT07078604·20 enrolled

Ovarian Serous Tumor1 trial

A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients With Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer

Completed·NNational Cancer Institute (NCI)·Preclinical·NCT02101788·260 enrolled

Advanced Malignant Neoplasm1 trial

A Phase I Study of the NovoTTF-100L(P) System to Enhance Antitumor Activity in Patients With Predominant Hepatic Metastatic Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT03203525·38 enrolled

Endometrioid Adenocarcinoma1 trial

A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) With Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers With Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT04092270·55 enrolled

Sources

References

[1]
ClinicalTrials.gov — 87 trial records for Pegylated IFN-alpha 2b. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pegylated IFN-alpha 2b compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pegylated IFN-alpha 2b. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gynecologic Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GGynecologic Oncology Group

Pegylated IFN-alpha 2b

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Trials by Indication[1]

Breast Cancer13 trials

Multiple Myeloma8 trials

Liposomal Doxorubicin8 trials

Lymphoma8 trials

Fallopian Tube Cancer7 trials

Ovarian Cancer5 trials

Kaposi's sarcoma2 trials

Soft Tissue Sarcoma2 trials

Prostate Cancer2 trials

Endometrial Cancer2 trials

Diffuse Large B-Cell Lymphoma2 trials

Fallopian Tube Clear Cell Adenocarcinoma2 trials

Bile Duct Cancer1 trial

Gynecologic Cancer1 trial

Ductal Carcinoma in Situ1 trial

Pancreatic Cancer1 trial

Chronic Hepatitis1 trial

Primary Peritoneal Cancer1 trial

Renal Cell Carcinoma1 trial

Cervical Cancer1 trial

Patients With Advanced Solid Tumors1 trial

Chemotherapy1 trial

Patients With Solid Tumors1 trial

Hematologic Cancer1 trial

Stage IV Ovarian Epithelial Cancer1 trial

Cutaneous T-cell lymphoma1 trial

Mycosis Fungoides1 trial

Peritoneal Cancer1 trial

Metastatic Dedifferentiated Liposarcoma1 trial

Fallopian Tube High Grade Serous Adenocarcinoma1 trial

FIGO Stage IVA Ovarian Cancer1 trial

Plasma Cell Leukemia1 trial

Fallopian Tube Mucinous Adenocarcinoma1 trial

Locally Advanced Malignant Solid Neoplasm1 trial

Anatomic Stage IV Breast Cancer AJCC v81 trial

Ovarian Serous Tumor1 trial

Advanced Malignant Neoplasm1 trial

Endometrioid Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News